Skip to main content

Dyadic to Present at Upcoming Events

Written by Customer Service on . Posted in Public Companies.

JUPITER, Fla., May 03, 2021 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that the Company will participate in the following upcoming events:

KOL Fireside Chat
Title: The Potential of the Transformative Dyadic C1 Protein Technology in Helping Meet Global Health Challenges
Time: Tuesday, May 4, 2021 10:00 AM Eastern Time

The conversation will be moderated by Dr. David Bramhill, a veteran in the biotechnology industry with extensive experience using a wide array of protein production technologies.

The discussion will include the following Key Opinion Leaders (KOLs):

  • Alain Townsend, Ph.D. – Weatherall Institute – Oxford University
  • Albert Osterhaus, P.V.M, Ph.D. – Erasmus Medical Centre
  • Cecil Nick – Parexel (Clinical & Regulatory Support)
  • Joris Vandeputte – International Alliance for Biological Standardization

World Vaccine Congress
Presenter: Mark Emalfarb, CEO
Event Link: https://www.terrapinn.com/conference/world-vaccine-congress-washington/index.stm

Track: COVID-19 Vaccine Response & Approaches
Title: Dyadic C1-Cells – Flexible Scale Manufacturing of NexGen MonoValent & MultiValent Recombinant Antigen Vaccines & Antibodies
Time: Tuesday, May 4, 2021 4:30 PM to 4:45 PM Eastern Time

Track: COVID-19 Trials & Infectious Diseases
Title: DYADIC C1-CELLS – Realizing Full Global Potential of MonoValent and/or MultiValent Recombinant Antigen Vaccines & Antibodies
Time: Wednesday, May 5, 2021 5:00 PM to 5:15 PM Eastern Time

Track: COVID-19 Manufacture & Supply
Title: Dyadic C1- Cells, industrially proven hyper productive thermophilic filamentous fungus for manufacturing safe, effective and affordable recombinant protein antigen vaccines & antibodies for world population
Time: Thursday, May 6, 2021 3:30 PM to 3:45 PM Eastern Time

17th Annual PEGS Boston
Presenter: Mark Emalfarb, CEO
Track: Accelerating Vaccine Development for COVID-19
Title: Making Vaccines in Large Quantities, Flexible Commercial Scales More Affordable – C1 Cells
Time: Thursday May 13, 2021 2:40 PM -3:00 PM Eastern Time
Event Link: https://www.pegsummit.com/

Dyadic Management will be available during the events for one-one-one meetings. Interested industry partners may request a one-on-one meeting at jlatiuk@dyadic.com or contact Dyadic at (561) 743-8333. If you are registered for any of the events, you can also request a meeting through the event platform.

About Dyadic International, Inc.

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical protein production platform based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1. The C1 microorganism, which enables the development and large-scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Certain other research activities are ongoing which include the exploration of using C1 to develop and produce certain metabolites and other biologic products. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and improve access and cost to patients and the healthcare system, but most importantly save lives. 

Please visit Dyadic’s website at http://www.dyadic.com/ for additional information, including details regarding Dyadic’s plans for its biopharmaceutical business.

Contact:

Dyadic International, Inc.
Mark Emalfarb, CEO
Phone: (561) 743-8333
Email: memalfarb@dyadic.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.